JPMorgan Chase & Co. boosted its position in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 1.8% during the first quarter, according to its most recent disclosure with the SEC. The firm owned 122,497 shares of the biotechnology company’s stock after buying an additional 2,223 shares during the period. JPMorgan Chase & Co. owned 0.27% of United Therapeutics Corporation worth $16,583,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Ladenburg Thalmann Financial Services Inc. raised its position in United Therapeutics Corporation by 11.3% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 717 shares of the biotechnology company’s stock valued at $104,000 after buying an additional 73 shares during the period. Focused Wealth Management Inc bought a new position in United Therapeutics Corporation during the fourth quarter valued at $115,000. Advisory Services Network LLC bought a new position in United Therapeutics Corporation during the first quarter valued at $147,000. Daiwa Securities Group Inc. raised its position in United Therapeutics Corporation by 17.4% in the first quarter. Daiwa Securities Group Inc. now owns 1,350 shares of the biotechnology company’s stock valued at $183,000 after buying an additional 200 shares during the period. Finally, Campbell & CO Investment Adviser LLC bought a new position in United Therapeutics Corporation during the first quarter valued at $204,000.

Institutional Ownership by Quarter for United Therapeutics Corporation (NASDAQ:UTHR)

United Therapeutics Corporation (NASDAQ:UTHR) opened at 129.92 on Monday. United Therapeutics Corporation has a 1-year low of $97.52 and a 1-year high of $169.89. The stock has a 50 day moving average price of $124.34 and a 200-day moving average price of $138.37. The company has a market capitalization of $5.85 billion, a price-to-earnings ratio of 9.12 and a beta of 1.56.

United Therapeutics Corporation (NASDAQ:UTHR) last issued its earnings results on Wednesday, April 26th. The biotechnology company reported $3.89 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $3.12 by $0.77. United Therapeutics Corporation had a net margin of 41.04% and a return on equity of 34.74%. The business had revenue of $370.50 million during the quarter, compared to the consensus estimate of $399.59 million. During the same period last year, the business posted $3.02 EPS. United Therapeutics Corporation’s revenue was up .4% on a year-over-year basis. Equities analysts predict that United Therapeutics Corporation will post $14.42 earnings per share for the current year.

WARNING: “JPMorgan Chase & Co. Boosts Position in United Therapeutics Corporation (UTHR)” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international copyright and trademark law. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/06/19/jpmorgan-chase-co-boosts-position-in-united-therapeutics-corporation-uthr.html.

Several research firms have weighed in on UTHR. BidaskClub upgraded United Therapeutics Corporation from a “sell” rating to a “hold” rating in a report on Friday. Jefferies Group LLC restated a “sell” rating and set a $105.00 target price on shares of United Therapeutics Corporation in a report on Thursday, June 8th. ValuEngine lowered United Therapeutics Corporation from a “strong-buy” rating to a “buy” rating in a report on Friday, June 2nd. Wedbush restated an “outperform” rating and set a $213.00 target price (down from $229.00) on shares of United Therapeutics Corporation in a report on Thursday, April 27th. Finally, Cowen and Company restated a “hold” rating and set a $121.00 target price on shares of United Therapeutics Corporation in a report on Wednesday, April 26th. Three investment analysts have rated the stock with a sell rating, nine have issued a hold rating and three have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $137.09.

In other United Therapeutics Corporation news, CEO Martine A. Rothblatt sold 1,219 shares of the stock in a transaction dated Thursday, March 23rd. The shares were sold at an average price of $139.33, for a total value of $169,843.27. Following the transaction, the chief executive officer now directly owns 1,359 shares of the company’s stock, valued at approximately $189,349.47. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Tommy G. Thompson sold 2,000 shares of the stock in a transaction dated Wednesday, March 22nd. The shares were sold at an average price of $139.37, for a total transaction of $278,740.00. Following the completion of the transaction, the director now directly owns 2,000 shares in the company, valued at $278,740. The disclosure for this sale can be found here. Insiders sold a total of 17,020 shares of company stock valued at $2,154,373 over the last quarter. 7.50% of the stock is currently owned by company insiders.

United Therapeutics Corporation Company Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Receive News & Stock Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related stocks with our FREE daily email newsletter.